Time New York: Tue 17 Oct 18:28 pm  |  Save 15% on H&R Block Online

  
caticonslite_bm_alt

Masimo (MASI) Launches Trace Data and Reporting Tool in US

Zacks

Masimo Corporation MASI recently announced the release of its proprietary patient data visualization and reporting software, Trace, in the United States. It is specifically designed for Masimo Root and Radical-7 monitors.
Trace can communicate with Masimo devices via high-speed wired or wireless connections, with the ability to download up to 96 hours of patient data in seconds, aiding workflow efficiencies. It can provide analytics the determination of the minimum, maximum and mean values for each measurement, the percentage of time spent at defined parameter thresholds, threshold crossing counts and the duration of desaturation events. Trace also supports visual tools such as trend graphs, histograms and event annotations.

Year to date, Masimo has outperformed the industry in terms of price. The company has returned 29.2% compared with the sub-industry’s increase of 20.7%. Also, the current return is higher than the S&P 500’s gain of 12.6% over the same time frame.


Considering bountiful opportunities for Advanced Monitoring Technologies in the global market, the launch instills investors’ confidence in the stock. A research report by Markets And Markets reveals that niche market is expected to reach a worth of $15.01 billion globally by 2022, at a CAGR of 8.5%.

Additionally, Masimo’s long-term growth fundamentals are strong. The company, based in Irvine, CA, recorded a five-year CAGR of 8.5% for revenues and 9.1% for adjusted earnings per share. Masimo has particularly witnessed an improvement in earnings over the last three years.

Masimo develops, manufactures and markets a family of non-invasive monitoring systems. The latest development would significantly fortify the company’s position in niche markets.

Zacks Rank & Key Picks

Masimo carries a Zacks Rank #3 (Hold).

Some better-ranked stocks in the medical sector are Orthofix International N.V. OFIX, Luminex Corporation LMNX and IDEXX Laboratories, Inc IDXX. Orthofix International and Luminex Corporation sport a Zacks Rank #1 (Strong Buy), while IDEXX Laboratories carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Orthofix International has a long-term expected earnings growth rate of 11.8%. The stock has surged roughly 39.1% over the last six months.

Luminex Corporation has a long-term expected earnings growth rate of 16.3%. The stock has rallied 14.1% over the last six months.

IDEXX Laboratories has a long-term expected earnings growth rate of 19.8%. The stock has climbed 39.2% over a year’s time.

5 Trades Could Profit ""Big-League"" from Trump Policies

If the stocks above spark your interest, wait until you look into companies primed to make substantial gains from Washington's changing course.

Today Zacks reveals 5 tickers that could benefit from new trends like streamlined drug approvals, tariffs, lower taxes, higher interest rates, and spending surges in defense and infrastructure.

See these buy recommendations now >>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

To read this article on Zacks.com click here.
<-- You can share this post with your network,
or give us your opinion and leave a comment.
Be sure to check our RSS feeds for updates.